NRX PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.04 USD | +0.66% |
|
-40.62% | -33.91% |
| Apr. 18 | NRx Pharmaceuticals Receives Notice of Listing Compliance From Nasdaq | MT |
| Apr. 18 | Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 28.89M |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 69.96% |
More Fundamentals
* Assessed data
More news
Latest transcript on NRx Pharmaceuticals, Inc.
More press releases
More news
| 1 day | +0.66% | ||
| 1 week | -40.62% | ||
| Current month | -35.58% | ||
| 1 month | -36.80% | ||
| 3 months | -28.44% | ||
| 6 months | +6.63% | ||
| Current year | -33.91% |
1 week
3.00
5.20
1 month
3.006.00
Current year
2.807.33
1 year
2.2112.00
3 years
2.21488.00
5 years
2.21769.90
10 years
2.21769.90
| Managers | Title | Age | Since |
|---|---|---|---|
Stephen Willard
CEO | Chief Executive Officer | 63 | 22-07-11 |
Jonathan Javitt
FOU | Founder | 67 | 17-09-17 |
Richard Narido
DFI | Director of Finance/CFO | 46 | 23-09-12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jonathan Javitt
FOU | Founder | 67 | 17-09-17 |
Stephen Willard
CEO | Chief Executive Officer | 63 | 22-07-11 |
Janet Rehnquist
BRD | Director/Board Member | - | Dec. 26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 3.04 | +0.66% | 231,976 |
| 24-04-18 | 3.02 | -27.75% | 768,977 |
| 24-04-17 | 4.18 | -2.79% | 128,826 |
| 24-04-16 | 4.3 | -12.24% | 275,970 |
| 24-04-15 | 4.9 | -4.30% | 205,939 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotes
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.02
USD
Average target price
37.5
USD
Spread / Average Target
+1,141.72%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -33.91% | 28.7M | |
| -1.42% | 41.35B | |
| +42.15% | 40.38B | |
| +1.97% | 39.05B | |
| -14.19% | 26.67B | |
| +1.82% | 24.07B | |
| -24.55% | 18.36B | |
| -4.07% | 11.68B | |
| +21.36% | 11.6B | |
| +8.20% | 11.15B |
- Stock Market
- Equities
- BRPA Stock
